Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regulax is a brand of stimulant laxatives developed and marketed by the German pharmaceutical company Krewel Meuselbach. The product line is primarily known for its herbal formulation, **Regulax Abführ-Würfel** (laxative cubes), which contains sennosides derived from Senna leaves and fruits. These sennosides act as prodrugs that are metabolized by colonic bacteria into active rheinanthrones. These active metabolites stimulate the myenteric plexus to increase colonic motility (peristalsis) and inhibit water and electrolyte reabsorption by modulating the activity of the Na+/K+-ATPase pump and downregulating aquaporin 3 channels. Another variant, **Regulax Picosulfat**, utilizes sodium picosulfate, which is similarly activated by bacterial enzymes in the gut to exert a stimulant effect. Regulax is indicated for the short-term treatment of occasional constipation and is available as an over-the-counter (OTC) medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Regulax.